Cargando…
HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?
BACKGROUND: Despite the extensive use of bevacizumab in a range of oncology indications, the US FDA revoked its approval for breast cancers, and multiple negative trials in several solid malignancies have been reported, so the need for predictive biomarkers has increased. The development of predicti...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426343/ https://www.ncbi.nlm.nih.gov/pubmed/31989465 http://dx.doi.org/10.1007/s41669-019-00193-8 |